In Germany, prostate cancer accounted for 22.7% of all new cases of cancer in men in 2016.1 Estimated incidence rate for prostate cancer is 170.8 per 100,000 population, which is above the European average of 153.9 per 100,000 per population.2 However, according to a 2016 report by the Robert Koch Institute, raw incidence rate per 100,000 population in 2016 was 144.7.1
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
1 Robert Koch Institute., Zentrum für Krebsregisterdaten., Krebs in Deutschland für 2015/2016. Accessible at https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/
Krebs_in_Deutschland/krebs_in_deutschland_node.html (last accessed March 2022)
2 European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-7$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)
In Germany, the estimated mortality for prostate cancer is 39 per 100,000 population, which is slightly higher than the EU27 average of 32.1 per 100,000 population.1
In general, Western European countries tend to achieve a lower prostate cancer mortality rate than Eastern European countries.2 However, according to a 2016 report by the Robert Koch Institute, raw mortality rate per 100,000 population in 2016 was 35.5 per 100,000 population.2
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
1 European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)
2 Robert Koch Institute. Zentrum für Krebsregisterdaten. Krebs in Deutschland für 2015/2016. Accessible at https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/
Krebs_in_Deutschland/krebs_in_deutschland_node.html (last accessed March 2022)
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
2 Robert Koch Institute. Zentrum für Krebsregisterdaten. Krebs in Deutschland für 2015/2016. Accessible at https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/
Krebs_in_Deutschland/krebs_in_deutschland_node.html (last accessed March 2022)
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
The National Decade against Cancer brings together representatives from politics, cancer research, the research funding system, healthcare, industry and society to strengthen cancer research. Launched by the Federal Ministry of Education and Research (BMBF), in cooperation with the Federal Ministry of Health, the initiative aims to mobilize people in Germany to address the topic of cancer research.
Analysis of the political profile of prostate cancer in Germany shows that it does not receive the attention that would be expected given the scale and impact of the disease. Between January 2015 and January 2020, prostate cancer was significantly less featured in political activity than other comparable cancers. For example, prostate cancer was mentioned in only four parliamentary reports, while breast cancer was mentioned in 16 reports. In addition, breast cancer was mentioned in six parliamentary debates while prostate cancer was only debated once. Breast cancer was also mentioned twice as many times in publications by the Ministry of Health (6 compared to 3).
Clinical guidelines for prostate cancer are set out in the 2021 Interdisciplinary guideline of the Quality S3 for early detection, Diagnosis and therapy of the different stages of the Prostate cancer. The recommended care pathway set out in the guidelines includes patient access to*:
Legend:
Recommendation included
Recommendation not included
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
1 European Society of Residents in Urology (ESRU). Germany. March 2018. Accessible at https://esru.eu/?q=germany (last accessed March 2022)
2 European Society of Residents in Urology (ESRU). Greece. March 2018. Accessible at https://esru.eu/?q=greece (last accessed March 2022)<br
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
2 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022) – average calculated from data included for individual countries.
Cancer medicines spend
€92 is spent on cancer medicines per capita in Germany, which is less than Austria but higher than the European average (the second highest in the EU).1 Western European countries tend to spend the most on cancer treatments with Greece and Estonia spending the least (€4 per capita).1
However, it is important to note that variations exist between pan-European and national datasets. Data from the German Statistische Bundesamt indicates the direct cost of cancer to be €242 per person.2
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
2 Statistisches Bundesamt, Statistisches Jahrbuch 2019. Page 153. Accessible at https://www.destatis.de/DE/Themen/Querschnitt/Jahrbuch/statistisches-jahrbuch-2019-dl.pdf?__blob=publicationFile (last accessed March 2022)
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
*Different data sources were used for Belgium, Hungary, Italy, Romania and the UK, which may use data from different years. See references below. No data was found for Cyprus, Luxembourg, Malta and Slovakia.
European Society of Residents in Urology (ESRU). Countries. March 2018. Accessible at https://esru.eu/?q=countries (last accessed March 2022)
Federal Public Service of Public Health, Safety of the Food Chain and the Environment. HWF STATAN 2019 (detailed statistics). 2019. Accessible at https://organesdeconcertation.sante.belgique.be/fr/documents/hwf-statan-2019-statistiques-detaillees (last accessed March 2022)
Boszormenyi-Nagy, G. Report on urological inpatient care based on 2018 data. Urologia Hungarica. Accessible at http://urologiahungarica.hu/index.php/2020/05/12/beszamolo-az-urologiai-fekvobeteg-ellatasrol-a-2018-as-adatok-alapjan/ (last accessed March 2022)
I.Stat. Personale sanitario. Accessible at http://dati.istat.it/Index.aspx?DataSetCode=DCIS_PERS_SANIT (last accessed March 2022)
Institutul National De Statistica. Activitatea Unitatilor Sanitare in Anul 2019. 2020. Accessible at https://insse.ro/cms/sites/default/files/field/publicatii/activitatea_unitatilor_sanitare_anul_2019.pdf (last accessed March 2022)
United Nations, Population Division, Department of Economic and Social Affairs. World Population Prospects 2019. Accessible at https://population.un.org/wpp/Download/Files/1_Indicators%20(Standard)/EXCEL_FILES/1_Population/
WPP2019_POP_F01_1_TOTAL_POPULATION_BOTH_SEXES.xlsx (last accessed March 2022)
British Association of Urological Surgeons and The Specialist Advisory Committee in Urology. Workforce Report. 2018. Accessible at https://www.baus.org.uk/_userfiles/pages/files/publications/
Workforce_Report_Sep%202018%20ver%201.1.pdf (last accessed March 2022)
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
The main prostate cancer patient organisation in Germany is:
Bundesverband Prostatakrebs Selbsthilfe
https://www.prostatakrebs-bps.de/
Reference Number: ONC_2021_0143_BE
Date of preparation: January 2022
